v3.22.2.2
Collaboration and License Agreements - Takeda Pharmaceutical Company Limited (Details)
$ in Thousands
12 Months Ended
Oct. 07, 2020
USD ($)
bundle
obligation
Sep. 30, 2022
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2020
USD ($)
Jan. 31, 2021
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Revenues   $ 243,231 $ 138,287 $ 87,992  
Deferred revenue, net of current portion   55,950 131,495    
Deferred revenue   74,099 111,055    
Takeda License Agreement | License and Co-Funding Agreement          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Cash received as due under collaboration agreement         $ 300,000
Number of distinct bundle | bundle 1        
Number of distinct performance obligations | obligation 1        
Initial transaction price $ 300,000        
Revenues   85,800 $ 90,800    
Contract assets   0      
Takeda License Agreement | License and Co-Funding Agreement | Deferred Revenue          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Deferred revenue, net of current portion   123,400      
Deferred revenue   67,400      
Takeda License Agreement | License and Co-Funding Agreement | Accrued Expenses          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Deferred revenue   $ 8,600      
Takeda License Agreement | License and Co-Funding Agreement | Minimum          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Percentage of eligible to receive tiered royalties on net sales 20.00%        
Takeda License Agreement | License and Co-Funding Agreement | Maximum          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Percentage of eligible to receive tiered royalties on net sales 25.00%        
Development regulatory and sales milestones payments         $ 595,000